vimarsana.com
Home
Live Updates
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma
Data Support 14 Days On/14 Days Off as Optimal Dosing Schedule; CFT7455 is Well Tolerated with Promising Signs of Anti-Myeloma Activity Completed Monotherapy…
Related Keywords
,
Data Support ,
Optimal Dosing Schedule ,
Well Tolerated ,
Promising Signs ,
Immunomodulatory Effects ,
Novel Multiple Myeloma Agents ,
News ,
Ggregator ,
Reaking News ,
Uration ,
Media ,